الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
SUMMARY
Patients diagnosed with COVID-19 may have a wide range of symptoms from mild to severe. Fever, cough and shortness of breath are the most common symptoms that have been reported advancedage; underlying comorbidities such as hypertension, diabetes, cardiovascular disease, and cerebrovascular disease are the risk factors that have been reported for developing into severe to critical cases
Our prospective observational study conducted on 60 patients diagnosed to have Covid-19 infection due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); proven via COVID-19 polymerase chain reaction (PCR) test .admitted to respiratory ICU in Beni-Suef university hospital of both sex .The study conducted on 60 patients, out of which 30 patients were offered Tocilizumab and 30 patients were offered high dose of methylprednisolone(2mg/kg) for comparing the efficacy of both modalities of treatment regarding hospital stay , Oxygen need , resolution of CT findings , need for mechanical ventilation and inflammatory marker levels.
This studyrevealed that:
Therapy with tocilizumab(TZ) was associated with better clinical outcome and improvement of inflammatory markers(CRP,Ferritin,D.dimer), reduction of length of oxygen therapy (days) (17.9 TZ vs MP 22.07) , lower percentage of discharging with oxygen (23.3% TZ vs 50% MP) , improvement of partial pressure of oxygen (PO2) (83.6 TZ vs 81.1 MP) ,oxygen saturation( SPO2) (96.3% TZ vs 95.3% MP) , Po2/Fio2 (397.6 TZ vs 387 MP) and radiological improvement ground glass opacity( GGO) (tocilizumab 36.7% vs methylprednisolone 43.3%) , fibrosis (tocilizumab 20% vs methylprednisolone 30%) and complete radiological resolution (tocilizumab 43.3% vs methylprednisolone 26.7%) in comparison with methylprednisolone.